Activation of FXR by CDCA inhibits proliferation of prostate cancer cells, reduces lipid anabolism via inhibiting Sterol Regulatory Element Binding Transcription Factor 1 (SREBF1) [270] and induces the expression of the tumor suppressor phosphatase and tensin homolog (PTEN) [271] (Table 6). This evidence concerns the gene SREBF1 and prostate carcinoma.